News Breaks |
|
|
| February 7, 2013 |
| 05:53 EDT |  | BMY, AMGN, GILD | Drug firms shift revenue abroad to lower taxes, WSJ reports
A number of big drug companies pay effective tax rates of 20% or more. Now they're taking steps to lower their taxes significantly, helping their bottom lines, reports the Wall Street Journal. While they don't specify their strategies, details can vary. But the efforts typically involve shifting revenue overseas where it can be taxed at a lower rate than in the U.S., experts say. Some companies also noted the tax benefit they will receive this year from a federal tax credit for research and development.Reference Link |
|
|
News For BMY;GILD;AMGN From The Last 14 Days Check below for free stories on BMY;GILD;AMGN the last two weeks. |
|
|
| May 24, 2013 |
| 07:20 EDT |  | GILD | Celgene, Gilead, and Biogen could go much higher, says Bernstein
 Subscribe for More Information |
|
| May 23, 2013 |
| 10:27 EDT |  | GILD | Gilead has a conference call hosted by JPMorgan
Subscribe for More Information |
|
| 06:02 EDT |  | BMY | Bristol-Myers implied volatility at upper end of index mean range
|
|
| 05:47 EDT | | BMY | Stocks with implied volatility movement; SKS BMY
Stocks with implied volatility movement; Saks (SKS), Bristol-Myers (BMY) according to IVolatility. |
|
| May 22, 2013 |
| 16:00 EDT | | BMY | Options Update; May 22, 2013
Subscribe for More Information |
|
| 10:33 EDT |  | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 16:51 EDT | | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
Subscribe for More Information |
| |
| 07:34 EDT | | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information |
|
| 06:30 EDT | | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
| |
|
|
|
|
